Decheng Capital Global Life Sciences Fund IV, L.P.
Decheng Capital Global Life Sciences Fund IV, L.P.'s purchase track record
Decheng Capital Global Life Sciences Fund IV, L.P. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/14/2025 | AARD | $20.00M | -25.6% | -18.9% | +5.5% |
| 1/29/2024 | CGON | $7.60M | +17.1% | -15.3% | +10.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
CG Oncology appoints Isabel Kalefonos as Chief Commercial Officer. CG Oncology announced the appointment of Isabel Kalefonos as its new chief commercial officer. The hire adds experienced biopharmaceutical leadership as the company prepares for a possible bladder cancer product launch. The addition may strengthen the commercial strategy ahead of upcoming market activities.
Transaction History
| AARD | ▲ Buy | Open Market | 625,000 | $10.0M | 2/14/2025 | View on chart |
| AARD | ▲ Buy | Open Market | 625,000 | $10.0M | 2/14/2025 | View on chart |
| AARD | ▼ Sell | Other | 333,412 | — | 2/14/2025 | View on chart |
| AARD | ▼ Sell | Other | 2,333,887 | — | 2/14/2025 | View on chart |
| CGON | ▼ Sell | Other | 3,628,198 | — | 1/29/2024 | View on chart |
| CGON | ▲ Buy | Open Market | 400,000 | $7.6M | 1/29/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD)
RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD). RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.